Extravasation of systemic hemato-oncological therapies

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 858-862

  Ener, R A ^a,c   Meglathery, S B ^a   Styler, M ^b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Antidotes; Chemotherpy extravasation; Irritant drugs; Vesicant drugs

Indexed keywords

ACLACINOMYCIN; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTIDOTE; ANTILEUKEMIC AGENT; BI(5 HYDROXYMETHYL 3,5 DIMETHYL 2 OXOMORPHOLIN 3 YL); BICARBONATE; BISANTRENE; BUTYLCRESOL; CHLORMETHINE; CORTICOSTEROID; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DIMETHYL SULFOXIDE; DOXORUBICIN; ESORUBICIN; ETOPOSIDE; HYALURONIDASE; HYDROCORTISONE; MITOMYCIN C; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; SODIUM THIOSULFATE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

BULLOUS SKIN DISEASE; BURNING SENSATION; CLINICAL TRIAL; COLD TREATMENT; DEBRIDEMENT; DISABILITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DNA BINDING; DRUG EXTRAVASATION; DRUG MECHANISM; DRUG METABOLISM; EDEMA; EMERGENCY; ERYTHEMA; FASCIA DISEASE; HEAT TREATMENT; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFLAMMATION; INJECTION PAIN; INTRAVENOUS CATHETER; PERIOSTEUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLISHING; REVIEW; SKIN INDURATION; SKIN NECROSIS; SKIN TOXICITY; SKIN ULCER; SOFT TISSUE DISEASE; TENDON DISEASE; TISSUE INJURY; TISSUE NECROSIS;

ANTINEOPLASTIC AGENTS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; HUMANS; INFUSIONS, INTRAVENOUS; SOFT TISSUE INJURIES; WOUNDS AND INJURIES;

EID: 3442881954     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh214     Document Type: Review

References (28)

1. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4: 41-60.
2. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety 1995; 12: 245-255.
3. Oncology Nursing Society, Powel LL (ed.): Cancer Chemotherapy Guidelines and Recommendation for Practice. Pittsburgh, PA: Oncology Nursing Press 1996.
4. Schneider SM, Distelhorst CW. Chemotherapy-induced emergencies. Semin Oncol 1989; 16: 572-578.
5. Dorr RT. Pharmacologic management of vesicant chemotherapy extravasations. In Dorr RT, Vonn Hoff DD (eds): Cancer Chemotherapy Handbook, 2nd edition. Norwalk, CT: Appleton & Lange 1993; 109-118.
6. Dorr RT, Dordal MS, Koenig LM et al. High levels doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion. Cancer 1999; 64: 2462-2464.
7. Sonneveld P, Wassenaar HA, Nooter K. Long persistence of doxorubicin in human skin after extravasation. Cancer Treatment Rep 1984; 68: 895-896.
8. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmcotherapy 1997; 17: 163-165.
9. Bertelli G, Gozza A, Forno JA et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851-2855.
10. Mayo DJ, Pearson DC. Chemotherapy extravasation: a consequence of fibrin sheath formation around the venous access devices. Oncology Nurse Forum 1995; 22: 675-680.
11. Tsavaris NB, Komitsopoulous P, Karagiaouris P et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992; 30: 330-333.
12. Ohnoshi T, Ohnuma T, Beranek JT et al. Combined effects of hyperthermia and anthracycline antibiotics on human tumor cells. J Natl Cancer Inst 1985; 74: 275-281.
13. Dorr RT, Alberts DS, Stone A. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treatment Rep 1985; 69: 431-437.
14. Harwood K, Gonin R. Short term vs. long term local cooling after doxorubicin extravasation: an ECOG study. Proc Am Soc Clin Oncol 1994; 13: 1544 (Abstr).
15. Dorr RT, Albert DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985; 74: 113-120.
16. Dorr RT, Snead K, Liddil JD. Skin ulceration of paclitaxel in a mouse skin model in vivo. Cancer 1996; 78: 152-156.
17. Laurie SW, Wilson KL, Kernahan DA et al. Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann Plastic Surg 1984; 13: 191-194.
18. Bertelli G, Dini D, Forno GB et al. Hyaluronidase as an antidote to extravasation to vinca alkaloids. J Cancer Res Clin Oncol 1994; 120: 505-506.
19. Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemother Pharmacol 1988; 22: 299-302.
20. Howell SB, Taetle R. Effect of sodium thiosulfate on cis-dichloro-diammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treatment Rep 1980; 64: 611-616.
21. Owen OE, Dellatorre DL, van Scott EJ et al. Accidental intramuscular injection of mechlorethamine. Cancer 1980; 45: 2225-2226.
22. Swingen BA, Powis O, Appel PL et al. Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and α-tocopherol. Cancer Res 1981; 41: 3395-3399.
23. Dorr RT, Soble MJ, Liddli JD et al. Mitomycin C toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. J Clin Oncol 1986; 4: 1399-1404.
24. Albenell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27: 347-361.
25. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety 1995; 12: 245-255.
26. Baur M, Kienzer HR, Rath T et al. Extravasation of oxaliplatin (Eloxatin®) - clinical course. Onkologie 2000; 23: 468-471.
27. Kennedy JG, Donahue JP, Hoang B et al. Vesicant characteristics of oxaliplatin following antecubital extravasation. Clin Oncol (R Coll Radiol) 2003; 15: 237-239.
28. Kretzschmar A, Pink D, Thuss-Patience P et al. Extravasation of oxaliplatin. J Clin Oncol 2003; 21: 4068-4069.